SFDA Alerts On Adverse Reactions Of Aciclovir And Cephradine
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has alerted health care professionals, pharmaceutical manufacturers and distributors and the public about adverse reactions associated with antiviral aciclovir and antibiotic cephradine. According to figures from the National Center for ADR Monitoring, problems attributed to the two drugs - acute renal impairment and blood in urine - are still outstanding. SFDA reminds physicians to conduct full risk-benefit analysis when choosing drugs, paying especially close attention to the adverse effects caused by aciclovir and cephradine. The relevant manufacturers should conduct in-depth research into the mechanisms of the drug-caused impairment, evaluate the overall risk-benefit of the two medicines and adopt timely effective measures to reduce recurrence of adverse incidents in similar drugs. (Click here for more - Chinese Language)